Warfarin dose requirement during induction correlates with CYP2C9 genetic polymorphism.

被引：0
|
作者：
Muszkat, M [1 ]
Elami, A [1 ]
Krasilnikov, I [1 ]
Caraco, Y [1 ]
机构：
[1] Hadassah Univ Hosp, IL-91120 Jerusalem, Israel
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2002年 / 71卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P37 / P37
页数：1
相关论文
共 50 条
  • [31] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
    Scordo, MG
    Pengo, V
    Spina, E
    Dahl, ML
    Gusella, M
    Padrini, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (06) : 702 - 710
  • [32] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Satoshi Yamaori
    Mika Kushihara
    Kyoko Koeda
    Ikuo Yamamoto
    Kazuhito Watanabe
    Forensic Toxicology, 2013, 31 : 70 - 75
  • [33] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Yamaori, Satoshi
    Kushihara, Mika
    Koeda, Kyoko
    Yamamoto, Ikuo
    Watanabe, Kazuhito
    FORENSIC TOXICOLOGY, 2013, 31 (01) : 70 - 75
  • [34] Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose
    Zhao, F
    Loke, C
    Rankin, SC
    Guo, JY
    Lee, HS
    Wu, TS
    Tan, T
    Liu, TC
    Lu, WL
    Lim, YT
    Zhang, Q
    Goh, BC
    Lee, SC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (03) : 210 - 219
  • [35] The influence of coagulation factor and CYP2C9 polymorphisms on warfarin dose
    Aquilante, CL
    Yarandi, HN
    Langaee, TY
    Tromberg, JS
    Lopez, LM
    Waddell, CD
    Johnson, JA
    CIRCULATION, 2003, 108 (17) : 424 - 424
  • [36] Warfarin dose requirements in a patient with the CYP2C9*14 allele
    Lee, Yee Ming
    Eggen, Jessica
    Soni, Vinay
    Drozda, Katarzyna
    Nutescu, Edith A.
    Cavallari, Larisa H.
    PHARMACOGENOMICS, 2014, 15 (07) : 909 - 914
  • [37] CYP2C9 polymorphisms and haplotypes: correlation with warfarin dose and metabolism
    King, BP
    Khan, TI
    Kamali, F
    Daly, AK
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 639 - 639
  • [38] CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin
    Karnik, Niteen D.
    Sridharan, Kannan
    Tiwari, D.
    Gupta, V.
    INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 (05) : 549 - 550
  • [39] Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirements
    King, BP
    Khan, T
    Kamali, F
    Daly, AK
    DRUG METABOLISM REVIEWS, 2003, 35 : 133 - 133
  • [40] In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose
    Tai, GY
    Farin, F
    Rieder, MJ
    Dreisbach, AW
    Veenstra, DL
    Verlinde, CLMJ
    Rettie, AE
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (07): : 475 - 481
12345